Exploring the Cardiotoxicity Spectrum of Anti-Cancer Treatments : Definition, Classification, and Diagnostic Pathways
Early detection and treatment of cancer have led to a noticeable reduction in both mortality and morbidity. However, chemotherapy and radiotherapy could exert cardiovascular (CV) side effects, impacting survival and quality of life, independent of the oncologic prognosis. In this regard, a high clinical index of suspicion is required by the multidisciplinary care team in order to trigger specific laboratory tests (namely natriuretic peptides and high-sensitivity cardiac troponin) and appropriate imaging techniques (transthoracic echocardiography along with cardiac magnetic resonance, cardiac computed tomography, and nuclear testing (if clinically indicated)), leading to timely diagnosis. In the near future, we do expect a more tailored approach to patient care within the respective community along with the widespread implementation of digital health tools.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Journal of clinical medicine - 12(2023), 4 vom: 17. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mauro, Ciro [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cancer therapy-related cardiovascular toxicity |
|---|
| Anmerkungen: |
Date Revised 01.03.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/jcm12041612 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353422835 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353422835 | ||
| 003 | DE-627 | ||
| 005 | 20231226055947.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/jcm12041612 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1178.xml |
| 035 | |a (DE-627)NLM353422835 | ||
| 035 | |a (NLM)36836147 | ||
| 035 | |a (PII)1612 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mauro, Ciro |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Exploring the Cardiotoxicity Spectrum of Anti-Cancer Treatments |b Definition, Classification, and Diagnostic Pathways |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 01.03.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Early detection and treatment of cancer have led to a noticeable reduction in both mortality and morbidity. However, chemotherapy and radiotherapy could exert cardiovascular (CV) side effects, impacting survival and quality of life, independent of the oncologic prognosis. In this regard, a high clinical index of suspicion is required by the multidisciplinary care team in order to trigger specific laboratory tests (namely natriuretic peptides and high-sensitivity cardiac troponin) and appropriate imaging techniques (transthoracic echocardiography along with cardiac magnetic resonance, cardiac computed tomography, and nuclear testing (if clinically indicated)), leading to timely diagnosis. In the near future, we do expect a more tailored approach to patient care within the respective community along with the widespread implementation of digital health tools | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a cancer therapy-related cardiovascular toxicity | |
| 650 | 4 | |a cardio-oncology | |
| 650 | 4 | |a chemotherapy | |
| 700 | 1 | |a Capone, Valentina |e verfasserin |4 aut | |
| 700 | 1 | |a Cocchia, Rosangela |e verfasserin |4 aut | |
| 700 | 1 | |a Cademartiri, Filippo |e verfasserin |4 aut | |
| 700 | 1 | |a Riccardi, Ferdinando |e verfasserin |4 aut | |
| 700 | 1 | |a Arcopinto, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Alshahid, Maie |e verfasserin |4 aut | |
| 700 | 1 | |a Anwar, Kashif |e verfasserin |4 aut | |
| 700 | 1 | |a Carafa, Mariano |e verfasserin |4 aut | |
| 700 | 1 | |a Carbone, Andreina |e verfasserin |4 aut | |
| 700 | 1 | |a Castaldo, Rossana |e verfasserin |4 aut | |
| 700 | 1 | |a Chianese, Salvatore |e verfasserin |4 aut | |
| 700 | 1 | |a Crisci, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a D'Assante, Roberta |e verfasserin |4 aut | |
| 700 | 1 | |a De Luca, Mariarosaria |e verfasserin |4 aut | |
| 700 | 1 | |a Franzese, Monica |e verfasserin |4 aut | |
| 700 | 1 | |a Galzerano, Domenico |e verfasserin |4 aut | |
| 700 | 1 | |a Maffei, Vincenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Marra, Alberto Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Mazza, Alfredo |e verfasserin |4 aut | |
| 700 | 1 | |a Ranieri, Brigida |e verfasserin |4 aut | |
| 700 | 1 | |a D'Agostino, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Rega, Salvatore |e verfasserin |4 aut | |
| 700 | 1 | |a Romano, Luigia |e verfasserin |4 aut | |
| 700 | 1 | |a Scagliarini, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Sepe, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Vriz, Olga |e verfasserin |4 aut | |
| 700 | 1 | |a Izzo, Raffaele |e verfasserin |4 aut | |
| 700 | 1 | |a Cittadini, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Bossone, Eduardo |e verfasserin |4 aut | |
| 700 | 1 | |a Salzano, Andrea |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical medicine |d 2012 |g 12(2023), 4 vom: 17. Feb. |w (DE-627)NLM230666310 |x 2077-0383 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2023 |g number:4 |g day:17 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/jcm12041612 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2023 |e 4 |b 17 |c 02 | ||